



**Jubilant Life Sciences Ltd.**

1A, Sector 16A, Noida – 201301, India

Tel.: +91 120 4361000

www.jubl.com

**Appointment of Mr. GP Singh as CEO - Jubilant Pharma**

***Noida (UP), India, Tuesday, January 06, 2015***

Jubilant Life Sciences Limited (JLL), an integrated Pharmaceuticals and Life Sciences Company announced today that Mr. Gurpartap Singh Sachdeva (Mr. GP Singh) has been appointed as CEO of Jubilant Pharma Ltd, a 100% wholly-owned subsidiary of JLL. Mr. Singh will have overall responsibility for the operations under Jubilant Pharma and will report to the Jubilant Pharma Board. He will be based in the United States.

Prior to Jubilant, Mr. Singh had served as President of Sun Pharmaceuticals, USA and contributed to the growth of Sun's US business. He has worked extensively both in India and in the US in various leadership roles pertaining to Strategy, M&A, Commercial and Operations.

The appointment of Mr. Singh as CEO of Jubilant Pharma strengthens the management structure of the company and follows the appointment of Mr. Pramod Yadav and Mr. Rajesh Srivastava as co-CEOs of the Life Science Ingredients business of JLL.

This is pursuant to the previously announced management consolidation of Pharmaceuticals and Life Science Ingredients under two independent verticals to decouple the Pharmaceuticals segment from the Life Science Ingredients segment thereby harnessing the true potential in each businesses to aid focused faster growth for the company.

Commenting on the occasion, **Mr. Shyam S. Bhartia, Chairman and Managing Director and Mr. Hari S. Bhartia, Co- Chairman and Managing Director, Jubilant Life Sciences Limited said:** "We are pleased to welcome Mr. Singh into the Jubilant family to complete our pharma consolidation. Our Pharmaceuticals segment has attained significant scale and the businesses therein have great potential for growth. Mr. Singh's rich experience in Pharmaceuticals industry will help the company to enhance its focus and competitiveness thereby unlocking shareholder value."

**About Jubilant Life Sciences**

Jubilant Life Sciences Limited is a global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Generics, Specialty Pharmaceuticals and Life Science Ingredients. It also provides Services in Contract Manufacturing and Drug Discovery and Development. The Company's strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services across the value chain. With 10 world-class manufacturing facilities in India, US and Canada and a team of about 6,200 multicultural people across the globe, the Company is committed to deliver value to its customers spread across over 100 countries. The Company is well recognized as a 'Partner





of Choice' by leading pharmaceuticals and life sciences companies globally.  
For more info: [www.jubl.com](http://www.jubl.com).

**For more information please contact:**

**For Investors**

Ravi Agrawal  
Jubilant Life Sciences Limited  
Ph: +91-120 436 1002  
E-mail: [ravi\\_agrawal@jubl.com](mailto:ravi_agrawal@jubl.com)

Siddharth Rangnekar  
Citigate Dewe Rogerson  
Tel: +91 22 6645 1209  
E-mail: [siddharth@cdr-india.com](mailto:siddharth@cdr-india.com)

Anupam Jain  
Jubilant Life Sciences Limited  
Ph: +91-120 436 1021  
E-mail: [anupam\\_jain@jubl.com](mailto:anupam_jain@jubl.com)

Karl Kolah  
Citigate Dewe Rogerson  
Tel: +91 22 6645 1220  
E-mail: [karl@cdr-india.com](mailto:karl@cdr-india.com)

**For Media**

Neha Garg  
Jubilant Life Sciences Limited  
Ph: +91-120 436 1067  
E-mail: [neha\\_garg@jubl.com](mailto:neha_garg@jubl.com)

Saurabh Gupta  
Perfect Relations  
Ph: +91 9818075578  
E-mail: [sgupta@perfectrelations.com](mailto:sgupta@perfectrelations.com)

*Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.*